ArticleNutrition & diabetes2026
GULP1 enhances GLUT4 translocation by counteracting ACAP1-ARF6 inhibition.
Article in Nutrition & diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe molecular underpinnings of obesity-induced insulin resistance, a key driver of type 2 diabetes mellitus (T2DM), remain incompletely understood, limiting targeted therapies. While our prior work revealed that miR‑548ab impairs glucose homeostasis by downregulating GULP1, the precise mechanism by which GULP1 regulates insulin sensitivity, particularly through the GLUT4 trafficking machinery, is unknown. This study aimed to elucidate the novel function and molecular basis of GULP1 in controlling insulin-stimulated GLUT4 translocation and systemic glucose metabolism.
methodsBioinformatics analysis predicted interactions between GULP1 and GLUT4 vesicle regulators (ACAP1, ARF6). In vitro and in vivo models were used to assess GULP1's effects on glucose uptake and GLUT4 translocation. Insulin resistance was evaluated via glucose tolerance tests and insulin sensitivity assays. Mechanistic studies investigated how GULP1 promotes insulin-mediated GLUT4 translocation to the plasma membrane by alleviating ACAP1-induced inhibition of ARF6 activity.
resultsGULP1 significantly enhanced glucose uptake in adipocytes and muscle cells by promoting GLUT4 translocation to the plasma membrane. In obese mice, GULP1 overexpression improved insulin sensitivity and glucose tolerance. Mechanistically, GULP1 counteracted ACAP1's inhibition of ARF6 activity, thereby facilitating insulin-stimulated GLUT4 trafficking.
conclusionGULP1 can bind to ACAP1 and ARF6, and alleviate the inhibitory effect of ACAP1 on ARF6 activity, thereby enhancing insulin-mediated glucose uptake and improving insulin sensitivity in obese mice. This study reveals a novel mechanism of GULP1 in glucose metabolism and provides a new therapeutic target for treating obesity-related metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.